Nuthinbut, I think Burger should sit down and read the latest amended S1. I seriously doubt his being aware of the true status of Inverness nor Abbott. It has now been made very clear that Abbott is doing abolutely nothing with RECAF.
Inverness may or may not be working on RECAF but we do know they are not planning to sell a RECAF test on their mass analyzers. If you are not aware, that is the only reason to obtain a semi-exclusive license, to use RECAF with the mass analyzers. There goes any potential large profits right out the door. Now it would be a high priced point of care. With a royalty of $2 per test on a low use point of care device, the profits for BioCurex would not be much even if Inverness does proceed with the triage in a few years.
IMO, the brokers affiliated with Paulson will read the prospectus very carefully before placing any of the stock with their clients. Once you remove Abbott from the picture and also put Inverness as a long term possibility for even the low royalty stream, any investor would be betting on the success of Dog RECAF or any other type of product BioCurex might attempt to sell.
The big question is why Moro registered the "Oncopetdiagnostics.com" for himself and not for BioCurex?
Also, why would he need a perpetual license for himself on RECAF?
If Moro had any confidence in the success of BioCurex, why would he do that?
The answer is that Moro might be able to sell enough products to make a small profit for himelf and his lab but not enough to satisfy the debts of BioCurex.
News 
Market Data 
Discover 
